Synlogic Inc (NASDAQ:SYBX) Sees Large Increase in Short Interest

Synlogic Inc (NASDAQ:SYBX) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 353,100 shares, a growth of 7.2% from the June 30th total of 329,400 shares. Based on an average daily trading volume, of 338,600 shares, the short-interest ratio is presently 1.0 days. Approximately 1.9% of the shares of the company are sold short.

Shares of SYBX opened at $2.26 on Friday. Synlogic has a twelve month low of $1.35 and a twelve month high of $5.89. The company has a current ratio of 18.68, a quick ratio of 18.69 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $74.22 million, a P/E ratio of -1.35 and a beta of 2.21. The firm’s 50-day moving average is $2.11 and its two-hundred day moving average is $2.21.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings data on Friday, May 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03). The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.73 million. Synlogic had a negative net margin of 2,733.25% and a negative return on equity of 33.46%. Analysts predict that Synlogic will post -1.85 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in SYBX. Renaissance Technologies LLC raised its position in Synlogic by 96.0% during the fourth quarter. Renaissance Technologies LLC now owns 301,272 shares of the biotechnology company’s stock worth $777,000 after acquiring an additional 147,600 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Synlogic by 197.2% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 42,500 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 28,200 shares during the last quarter. Parametric Portfolio Associates LLC grew its holdings in Synlogic by 79.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 142,779 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 63,289 shares during the last quarter. Two Sigma Advisers LP increased its position in Synlogic by 54.9% during the first quarter. Two Sigma Advisers LP now owns 323,500 shares of the biotechnology company’s stock worth $556,000 after buying an additional 114,600 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Synlogic by 2.4% in the first quarter. State Street Corp now owns 302,915 shares of the biotechnology company’s stock worth $521,000 after acquiring an additional 7,162 shares during the last quarter. Institutional investors and hedge funds own 49.62% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Synlogic in a research note on Friday, May 22nd. Oppenheimer reissued a “hold” rating on shares of Synlogic in a research note on Sunday, May 10th. Finally, Zacks Investment Research downgraded shares of Synlogic from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Synlogic currently has a consensus rating of “Buy” and an average target price of $8.95.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Featured Article: What is the Beige Book?

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.